

# Beverly Moy

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8842980/beverly-moy-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151  
papers

3,857  
citations

31  
h-index

61  
g-index

168  
ext. papers

5,104  
ext. citations

5.1  
avg, IF

5.28  
L-index

#	Paper	IF	Citations
151	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102647	2.2	6
150	Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2022</b> , 20, 136-143	7.3	3
149	Abstract P3-13-01: Association of polygenic risk score with 2 year risk of poor prognosis breast cancer. <i>Cancer Research</i> , <b>2022</b> , 82, P3-13-01-P3-13-01	10.1	
148	Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer. <i>Cancer Research</i> , <b>2022</b> , 82, P3-09-11-P3-09-11	10.1	
147	Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation. <i>Cancer Research</i> , <b>2022</b> , 82, P1-18-22-P1-18-22	10.1	
146	Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). <i>Cancer Research</i> , <b>2022</b> , 82, P1-14-02-P1-14-02	10.1	
145	Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App. <i>Cancer Research</i> , <b>2022</b> , 82, P4-12-08-P4-12-08	10.1	
144	Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors. <i>Cancer Research</i> , <b>2022</b> , 82, P3-23-02-P3-23-02	10.1	
143	Abstract PD5-11: Pilot study to assess prolonged nightly fasting in breast cancer survivors (LONGFAST). <i>Cancer Research</i> , <b>2022</b> , 82, PD5-11-PD5-11	10.1	
142	Abstract P3-16-01: Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC). <i>Cancer Research</i> , <b>2022</b> , 82, P3-16-01-P3-16-01	10.1	
141	CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2022</b> , 20, CLO22-033	7.3	3
140	Assessment of patient navigation programs for breast cancer patients across the city of Boston. <i>Supportive Care in Cancer</i> , <b>2021</b> , 1	3.9	0
139	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 1-8	7.3	4
138	Antibody drug conjugates for patients with breast cancer. <i>Current Problems in Cancer</i> , <b>2021</b> , 45, 100795	2.3	1
137	Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and prior HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 188, 449-458	4.4	
136	Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 540-540	2.2	1
135	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3059-3059	2.2	

134	Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1570-1570	2.2	1
133	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , <b>2021</b> , 26, e1327-e1338	5.7	7
132	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , <b>2021</b> , 26, 827-834	5.7	4
131	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3938-3958	2.2	11
130	Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. <i>Clinical Breast Cancer</i> , <b>2021</b> , 21, e88-e95	3	1
129	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , <b>2021</b> , 21, 80-91.e7	3	52
128	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3404-3413	12.9	2
127	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 797-804	7.3	3
126	Disparities in phase 1 cancer clinical trial enrollment. <i>Cancer</i> , <b>2021</b> , 127, 4464-4469	6.4	0
125	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5818-5827	12.9	3
124	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 103	7.8	1
123	Financial toxicity, symptom burden, illness perceptions, and communication confidence in cancer clinical trial participants.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 86-86	2.2	1
122	Implementing a patient navigation program to improve adherence with cancer treatment for community health center patients newly diagnosed with cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 103-103	2.2	0
121	Illness perceptions, financial toxicity, symptom burden, and survival in cancer clinical trial (CCT) participants.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 160-160	2.2	
120	The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 1078155220971751	1.7	0
119	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , <b>2020</b> , 26, 1280-1284	50.5	34
118	Identification of Somatic Acquired Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4852-4862	12.9	7
117	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , <b>2020</b> , 395, 817-827	40	116

116	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 262-272	59.2	12
115	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2838-2848	12.9	132
114	Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. <i>BMC Cancer</i> , <b>2020</b> , 20, 347	4.8	5
113	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii147-ii147	1	
112	Randomized trial of a collaborative palliative and oncology care intervention to improve communication about end-of-life care in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1008-1008	2.2	2
111	Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1077-1077	2.2	9
110	Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1094-1094	2.2	1
109	Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 531-531	2.2	2
108	Medical oncologists' perceptions of clinical trials for underrepresented populations.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e19062-e19062	2.2	
107	Factors associated with frequent insomnia among breast cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e24098-e24098	2.2	
106	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2529-2529	2.2	
105	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer.. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 1246-1262	3.6	5
104	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With $\geq$ HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3138-3149	2.2	150
103	A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 183, 515-524	4.4	8
102	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , <b>2020</b> , 15, 198	4.2	2
101	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, 145-151.e2	3	10
100	Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study. <i>Cancer</i> , <b>2019</b> , 125, 4532-4540	6.4	4
99	Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 176, 303-310	4.4	8

98	Expanding Access to Cancer Clinical Trials for Patients With Mental Illness. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1524-1528	2.2	5
97	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 39	8.3	11
96	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1868-1875	2.2	120
95	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1081-1089	2.2	159
94	Blood-based monitoring identifies acquired and targetable driver mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , <b>2019</b> , 3, 18	9.8	13
93	Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. <i>Medical Decision Making</i> , <b>2019</b> , 39, 642-650	2.5	5
92	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1002-1002	2.2	61
91	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1028-1028	2.2	4
90	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1057-1057	2.2	16
89	Implementation of a brief screening tool to identify needs of cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e23075-e23075	2.2	1
88	Working together in cancer care: An academic community partnership for a diverse patient population.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 10525-10525	2.2	
87	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 720-727	6.6	37
86	Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 576-576	2.2	0
85	Addressing financial concerns of cancer clinical trial participants: Longitudinal outcomes of an equity intervention.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6566-6566	2.2	
84	Considering cost and value with patients in clinic.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e18905-e18905	2.2	
83	Delays in initial breast cancer treatment among black and white women in Boston.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e18620-e18620	2.2	
82	Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1021-1021	2.2	
81	Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1020-1020	2.2	2

80	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO1801132	2.2	29
79	NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , <b>2018</b> , 20, vi190-vi190	1	78
78	Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 733-740	4.4	8
77	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 163, 535-544	4.4	14
76	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3978-3986	3.2	90
75	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary. <i>Journal of Oncology Practice</i> , <b>2017</b> , 13, 822-824	3.1	6
74	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. <i>Oncologist</i> , <b>2017</b> , 22, 1039-1048	5.7	76
73	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1688-1700	21.7	328
72	Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer?. <i>Clinical Journal of Oncology Nursing</i> , <b>2017</b> , 21, E99-E105	1.1	4
71	Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). <i>Biomedical Optics Express</i> , <b>2017</b> , 8, 555-569	3.5	15
70	TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1005-1005	2.2	28
69	FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1013-1013	2.2	5
68	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1046-1046	2.2	3
67	Impact of PIK3CA tumor mutation on the association of aspirin or NSAID use and time to breast cancer recurrence.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1521-1521	2.2	2
66	Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 511-511	2.2	35
65	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS1106-TPS1106	2.2	1
64	Breast cancer care redesign as an approach to streamline survivorship care: Outcomes and challenges.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9-9	2.2	
63	Are NCI-designated cancer centers websites linguistically accessible?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e18078-e18078	2.2	

62	No Conflict, No Interest. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1631-1632	13.4	1
61	The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?. <i>Oncologist</i> , <b>2016</b> , 21, 1411-1413	5.7	1
60	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , <b>2016</b> , 56, 85-92	7.5	4
59	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 367-377	21.7	339
58	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 945-52	2.2	121
57	Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 569-78	4.4	16
56	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 29-36	13.4	48
55	Financial burden in adult cancer survivors: Care affordability and accessibility.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6535-6535	2.2	4
54	Prospective study of the financial burden of cancer clinical trial patients referred to a cancer care equity program (CCEP).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e18056-e18056	2.2	
53	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 586-586	2.2	
52	Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e22-9	7.1	3
51	Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1477-1486	13.4	175
50	Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. <i>Oncologist</i> , <b>2016</b> , 21, 467-74	5.7	41
49	Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	32
48	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. <i>Cancer</i> , <b>2015</b> , 121, 1937-48	6.4	7
47	Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 622-30	4	59
46	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 685-96	7.5	7
45	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3621-7	2.2	118

44	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 56	8.3	21
43	The impact of industry on oncology research and practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , 130-7	7.1	14
42	Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 340-8	2.2	67
41	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 508-508	2.2	12
40	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 117-117	2.2	1
39	Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6553-6553	2.2	1
38	Financial burden of cancer clinical trials: Impact of an equity program intervention.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6501-6501	2.2	
37	Hospitalizations and emergency department use in cancer clinical trial patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 160-160	2.2	
36	Palliative care consultation for patients enrolled in cancer clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 139-139	2.2	
35	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3307-29	2.2	185
34	Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2142-50	2.2	155
33	American Society of Clinical Oncology policy statement on medicaid reform. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4162-7	2.2	25
32	Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. <i>Oncologist</i> , <b>2014</b> , 19, 348-9	5.7	17
31	Geriatric oncology for the 21st century: a call for action. <i>Journal of Oncology Practice</i> , <b>2014</b> , 10, 241-3	3.1	12
30	Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. <i>Oncologist</i> , <b>2014</b> , 19, 346-7	5.7	9
29	Debating the oncologist's role in defining the value of cancer care: our duty is to our patients. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4039-41	2.2	12
28	Value of cancer care: ethical considerations for the practicing oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , e146-9	7.1	4
27	Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 522-522	2.2	



26	Alleviating financial burden for cancer patients in clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 10-10	2.2	
25	Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. <i>Biomedical Optics Express</i> , <b>2013</b> , 4, 2911-24	3.5	21
24	Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2678-84	2.2	11
23	Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1006-1006	2.2	
22	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 630-630	2.2	
21	Risk perceptions in localized breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9534-9534	2.2	
20	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 533-533	2.2	
19	NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6557-6557	2.2	
18	Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 647-647	2.2	
17	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 145-145	2.2	
16	Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 147-147	2.2	
15	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 167-167	2.2	
14	Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 599-599	2.2	2
13	Core elements of the patient protection and affordable care act and their relevance to the delivery of high-quality cancer care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , e4-8	7.1	2
12	Association between financial relationships with commercial interests and research merit at the ASCO Annual Meeting (AM).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6095-6095	2.2	
11	Financial relationships with commercial interests (COI) among abstracts at the ASCO Annual Meeting.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6128-6128	2.2	
10	Lapatinib in HER2+ early breast cancer: Quality of life analysis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 604-604	2.2	
9	Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 596-596	2.2	

8	Patient navigator programs, cancer disparities, and the patient protection and affordable care act. <i>Oncologist</i> , <b>2011</b> , 16, 926-9	5.7	23
7	American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3816-24	2.2	105
6	Medical integrity up in smoke? Conflicts of interest and the lung cancer screening controversy. <i>Oncologist</i> , <b>2008</b> , 13, 474-6	5.7	5
5	TEACH: Tykerb evaluation after chemotherapy. <i>Clinical Breast Cancer</i> , <b>2007</b> , 7, 489-92	3	25
4	Lapatinib-associated toxicity and practical management recommendations. <i>Oncologist</i> , <b>2007</b> , 12, 756-65	5.7	91
3	Lapatinib: current status and future directions in breast cancer. <i>Oncologist</i> , <b>2006</b> , 11, 1047-57	5.7	120
2	Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4790-3	12.9	49
1	Barriers to repeat mammography: cultural perspectives of African-American, Asian, and Hispanic women. <i>Psycho-Oncology</i> , <b>2006</b> , 15, 623-34	3.9	56